Tonix Pharmaceuticals
Logotype for Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals (TNXP) investor relations material

Tonix Pharmaceuticals TD Cowen 46th Annual Health Care Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Tonix Pharmaceuticals Holding Corp
TD Cowen 46th Annual Health Care Conference summary4 Mar, 2026

Key product and market updates

  • Focused on the launch of Tonmya, a first-in-class, sublingual treatment for fibromyalgia, approved in August and launched in November, with $1.4 million in net sales reported for the initial period.

  • Tonmya targets disturbed sleep in fibromyalgia, addressing a high unmet need among an estimated 10 million U.S. adults, with potential expansion to long COVID patients.

  • Commercial strategy includes 90 field reps targeting the top 5% of prescribers, robust patient access programs, and a WAC of $1,860/month.

  • Existing migraine products Tosymra and Zembrace are being deprioritized in promotion.

  • Company maintains $208 million in cash, no debt, and a simple capital structure.

Clinical and scientific insights

  • Tonmya’s unique sublingual, transmucosal formulation enables durable pain relief, with clinical trials showing significant and clinically meaningful reductions in pain.

  • Most common side effects are mild oral symptoms; no weight, blood pressure, cognitive, or sexual dysfunction changes observed.

  • Tonmya is a non-opioid analgesic, aligning with healthcare priorities to reduce opioid use in chronic pain.

  • Fibromyalgia is underdiagnosed and undertreated, with many patients receiving inappropriate opioid prescriptions.

  • Educational efforts aim to improve prescriber knowledge and promote holistic treatment approaches.

Pipeline and future plans

  • Advancing a Lyme disease prophylactic (licensed from UMass) with a planned human challenge study in 2027; aims for annual dosing.

  • TNX-102 SL being developed for major depressive disorder (study starting mid-year) and acute stress disorder (in partnership with UNC, DoD-funded).

  • Additional programs include a monoclonal antibody for kidney transplant (phase II starting mid-year) and an intranasal oxytocin for Prader-Willi syndrome (study planned for Q1 2027).

  • Multiple partnerships with leading institutions support pipeline development.

  • Company expects significant milestones in 2026 and 2027, including key clinical trial initiations.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Tonix Pharmaceuticals earnings date

Logotype for Tonix Pharmaceuticals Holding Corp
Q4 202520 Mar, 2026
Tonix Pharmaceuticals
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Tonix Pharmaceuticals earnings date

Logotype for Tonix Pharmaceuticals Holding Corp
Q4 202520 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing therapies for central nervous system disorders, rare diseases, and infectious diseases. The company’s pipeline includes treatments for conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, and long COVID. Tonix Pharmaceuticals also explores vaccine and antiviral drug candidates for infectious disease prevention and treatment. The company is headquartered in Chatham, New Jersey, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage